Oryzon to initiate phase II ESCAPE study of vafidemstat in severely ill COVID-19 patients in Spain April 27, 2020
SARS-CoV-2 requires ACE2 and TMPRSS2 for cell entry, which may be blocked by a TMPRSS2 inhibitor April 27, 2020
RSS